Diagnostic plasma protein signatures in sporadic and BRCA1/2 breast cancer patients via targeted proteomics.
Blood protein patterns can now distinguish inherited breast cancer from sporadic cases, potentially guiding who needs genetic testing and tailored surveillance.
This Breast Cancer Research study employs targeted mass spectrometry proteomics to identify plasma protein signatures that differentiate sporadic breast cancer from BRCA1/2-associated cases, advancing the concept of protein-based liquid biopsy for hereditary breast cancer. The distinct proteome profiles could enable pre-screening blood tests to guide BRCA testing and surveillance protocols.
What the study was
- Study design
- proteomics_case_control
- Population
- Sporadic and BRCA1/2-mutated breast cancer patients
- Category
- Early Detection
- Maturity
- Exploratory
- Journal
- Breast Cancer Res
Why it surfaced
Targeted proteomics in high-risk breast cancer populations extends the liquid biopsy repertoire beyond cfDNA; Breast Cancer Research is high-impact; BRCA1/2 hereditary cancer is a clinically relevant subset with clear unmet need for non-invasive monitoring.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.